Zacks: Analysts Expect Johnson & Johnson (JNJ) Will Announce Earnings of $1.95 Per Share

Wall Street analysts expect that Johnson & Johnson (NYSE:JNJ) will report $1.95 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Johnson & Johnson’s earnings, with the highest EPS estimate coming in at $1.97 and the lowest estimate coming in at $1.93. Johnson & Johnson reported earnings of $1.74 per share in the same quarter last year, which would indicate a positive year over year growth rate of 12.1%. The firm is scheduled to issue its next earnings results on Tuesday, January 22nd.

On average, analysts expect that Johnson & Johnson will report full-year earnings of $8.16 per share for the current fiscal year, with EPS estimates ranging from $8.15 to $8.18. For the next fiscal year, analysts expect that the business will report earnings of $8.68 per share, with EPS estimates ranging from $8.50 to $8.80. Zacks’ EPS averages are an average based on a survey of analysts that follow Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.02. The business had revenue of $20.35 billion during the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. Johnson & Johnson’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.90 earnings per share.

Several brokerages have commented on JNJ. Wells Fargo & Co reissued an “outperform” rating and set a $160.00 target price on shares of Johnson & Johnson in a research note on Friday, September 14th. Credit Suisse Group boosted their target price on Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research note on Wednesday. Raymond James boosted their target price on Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Wednesday. HC Wainwright reissued a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday. Finally, ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson currently has an average rating of “Hold” and a consensus target price of $144.25.

NYSE JNJ traded up $0.04 during trading on Thursday, hitting $139.50. 7,871,900 shares of the company’s stock were exchanged, compared to its average volume of 6,974,722. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. The company has a market cap of $370.70 billion, a price-to-earnings ratio of 19.11, a PEG ratio of 2.19 and a beta of 0.70. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.32.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be paid a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.58%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

In other news, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the transaction, the chief operating officer now owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of the company’s stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Phocas Financial Corp. boosted its holdings in Johnson & Johnson by 999,927.7% in the second quarter. Phocas Financial Corp. now owns 129,463,583 shares of the company’s stock valued at $1,571,000 after acquiring an additional 129,450,637 shares during the last quarter. Glenmede Trust Co. NA boosted its holdings in shares of Johnson & Johnson by 149.8% during the 2nd quarter. Glenmede Trust Co. NA now owns 22,174,682 shares of the company’s stock worth $2,690,676,000 after buying an additional 13,295,992 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Johnson & Johnson by 4.7% during the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after buying an additional 7,853,141 shares in the last quarter. Boston Partners boosted its holdings in shares of Johnson & Johnson by 68.7% during the 1st quarter. Boston Partners now owns 12,783,909 shares of the company’s stock worth $1,638,258,000 after buying an additional 5,207,124 shares in the last quarter. Finally, Fundsmith Equity Fund L.P. bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $552,762,000. 66.67% of the stock is owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Moving Average (MA)

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply